|
|
Line 1: |
Line 1: |
| __NOTOC__
| | Phenotype: |
| {{SI}}
| | Classic salt wasting |
| {{CMG}}; {{AE}} {{CZ}}; {{Ammu}}
| | |
| | | Classic simple virilizing |
| {{SK}} CAH; Adrenogenital syndrome
| | |
| | | Nonclassic |
| ==Overview==
| | |
| Congenital adrenal hyperplasia is a group of [[autosome|autosomal]] [[recessive]] [[disease]]s that result from multiple [[genetic]] mutations. The genes encode a number of enzymes that mediate the adrenal glands [[steroidogenesis]] pathway. As a result, mutations in such genes will result in various enzyme deficiencies that lead to a disequilibrium of the biochemical reactions mediating the production of cortisol, aldesterone, and androgens.<ref name="Warrell2005">{{cite book|author=David A. Warrell|title=Oxford textbook of medicine: Sections 18-33|url=https://books.google.com/books?id=hL1NKQJlY1IC&pg=PA261|accessdate=14 June 2010|year=2005|publisher=Oxford University Press|isbn=978-0-19-856978-7|pages=261–}}</ref> The outcome of congenital adrenal hyperplasia is either an excessive or deficient production of the aforementioned hormones, which alters the development of both [[primary sex characteristic|primary]] and [[secondary sex characteristic]]s among affected patients.<ref name="MilunskyMilunsky2010">{{cite book|author1=Aubrey Milunsky|author2=Jeff Milunsky|title=Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment|url=https://books.google.com/books?id=oKCmA4dOYtMC&pg=PA600|accessdate=14 June 2010|date=29 January 2010|publisher=John Wiley and Sons|isbn=978-1-4051-9087-9|pages=600–}}</ref> Congenital adrenal hyperplasia may be classified according to
| | |
| biochemical enzyme deficiency into commonly five subtypes: [[lipoid congenital adrenal hyperplasia]], [[congenital adrenal hyperplasia due to 21-hydroxylase deficiency]], [[congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency]], [[congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency]], and [[congenital adrenal hyperplasia due to 11β-hydroxylase deficiency]].
| | ♂ |
| ===Congenital Adrenal Hyperplasia===
| | ♀ |
| * The figure below illustrates the biochemical reactions of the adrenal glands [[steroidogenesis]] pathway:
| | ♂ |
| <br>
| | ♀ |
| [[Image:DHEA1_svg.png|thumb|center|800px|Production of DHEA from Cholesterol. ([[Cortisol]] is a [[glucocorticoid]].)]]
| | ♂ |
| | | ♀ |
| ==Historical Perspective==
| | Age at diagnosis |
| | | Newborn-6m |
| ==Classification==
| | Newborn-1m |
| * Congenital adrenal hyperplasia may be classified according to biochemical enzyme deficiency into commonly the following types:
| | 2–4 y |
| <br>
| | Newborn-2 y |
| {{Familytree/start}}
| | Child-adult |
| {{Familytree|boxstyle=background: #E0FFFF;| | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | |A01=<div style="width: 20em; padding:0.5em;">'''Congenital Adrenal Hyperplasia'''</div>}}
| | Child-adult |
| {{Familytree|boxstyle=background: #E0FFFF;| | | | |,|-|-|-|-|v|-|-|-|-|+|-|-|-|-|v|-|-|-|-|.| | | | | | | | | | | | | |}}
| | Genitalia |
| {{Familytree|boxstyle=background: #E0FFFF;| | | | B01 | | | B02 | | | B03 | | | B04 | | | B05 | | | | | | | | | | | |B01= <div style="width: 15em; padding:0.5em;">[[Lipoid congenital adrenal hyperplasia]]</div>|B02= <div style="width: 15em; padding:0.5em;">[[Congenital adrenal hyperplasia due to 21-hydroxylase deficiency]]</div>|B03= <div style="width: 15em; padding:0.5em;"> [[Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency]]</div>|B04= <div style="width: 15em; padding:0.5em;"> [[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency]] </div>|B05= <div style="width: 15em; padding:0.5em;"> [[Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency]] </div>}}
| | Normal |
| {{Familytree/end}}
| | Ambiguous |
| <br>
| | Normal |
| ===Biochemistry===
| | Ambiguous |
| * The table below lists the specific biochemical abnormalities present among the different types of congenital adrenal hyperplasia:
| | Normal |
| <br>
| | +/− ↑ clitoris |
| {| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
| | Aldosterone |
| |valign=top|
| | ↓ |
| |+
| | |
| ! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Common Medical Term'''
| | Normal |
| | | |
| ! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''OMIM Number'''
| | Normal |
| | | |
| ! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Enzyme'''
| | Renin |
| | | ↑ |
| ! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Gene location'''
| | |
| | | May be ↑ |
| ! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Substrates'''
| | |
| | | Normal |
| ! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Products'''
| | |
| | | Cortisol |
| |-
| | ↓ |
| | | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
| | ↓ |
| ''' [[Congenital adrenal hyperplasia due to 21-hydroxylase deficiency|21-hydroxylase CAH]]'''
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | Normal |
| :{{OMIM|201910}}
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | 17-OH-progesterone |
| :P450c21
| | >20,000 ng/dl |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :6p21.3
| | >10,000–20,000 ng/dl |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :17OH-progesterone→ <br/>[[Progesterone]]
| | 1,500–10,000 ng/dl (ACTH-stimulated) |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :11-deoxycortisol→<br/>[[11-deoxycorticosterone|DOC]]
| | Testosterone |
| | | ↑ In pre-puberty only |
| |-
| | ↑ |
| | | ↑ In pre-puberty only |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
| | ↑ |
| ''' [[Lipoid congenital adrenal hyperplasia|lipoid CAH]]<br/>(20,22-desmolase)'''
| | Variably ↑ in pre-puberty only |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | Variably ↑ |
| :{{OMIM|201710}}
| | Treatment |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | Glucocorticoid+ mineralocorticoid (+ sodium) |
| :StAR<br/>P450scc
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | Glucocorticoid (+ mineralocorticoid) |
| :8p11.2<br/>15q23-q24
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | Glucocorticoid, if symptomatic |
| :Transport of [[cholesterol]]→<br/>[[cholesterol]]
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | Somatic growtha |
| :Into mitochondria→<br/>[[Pregnenolone]]
| | -2-3 sd, husky-obese |
| |-
| | |
| | | -1-2 sd |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
| | |
| ''' [[Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency|17α-hydroxylase CAH]]'''
| | ?-1 sd |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :{{OMIM|202110}}
| | Incidenceb |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | 1/20,000 |
| :P450c17
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | 1/60,000 |
| :10q24.3
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | 1/1000 |
| :[[pregnenolone]]→<br/>[[progesterone]]→<br/>17OH-pregnenolone→
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | Typical mutationsc |
| :17OH-pregnenolone<br/>17OH-progesterone<br/>[[DHEA]]
| | Deletion |
| | | |
| |-
| | I172N |
| | | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
| | V281L |
| '''[[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency|3β-HSD CAH]]'''
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :{{OMIM|201810}}
| | Large conversion |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :3βHSD II
| | nt 656g |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :1p13
| | P30L |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :[[Pregnenolone]]→<br/>17OH-pregnenolone→<br/>[[DHEA]]→
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | nt 656g (“intron 2 g”) |
| :[[Progesterone]]<br/>17OH-progesterone<br/>[[androstenedione]]
| | |
| | | |
| |-
| | |
| | | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
| | |
| '''[[Congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency|11β-hydroxylase CAH]]'''
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | G110Δ8nt |
| :{{OMIM|202010}}
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :P450c11β
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :8q21-22
| | |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :11-deoxycortisol→<br/>DOC→
| | I236N/V237E/M239K |
| | style="padding: 5px 5px; background: #F5F5F5;"|
| | |
| :[[Cortisol]]<br/>[[Corticosterone]]
| | |
| |}
| | |
| | | |
| ==Pathophysiology==
| | |
| | | |
| ==Causes==
| | Q318X |
| | | |
| ==Differentiating {{PAGENAME}} from Other Diseases==
| | |
| | | |
| ==Epidemiology and Demographics==
| | |
| | | |
| ==Risk Factors==
| | |
| | | R356W |
| ==Screening==
| | |
| | | |
| ==Natural History, Complications, and Prognosis==
| | |
| | | |
| ==Diagnosis==
| | |
| ===Diagnostic Criteria===
| | % Enzymatic activityd |
| | | 0 |
| ===History and Symptoms===
| | |
| | | 1 |
| ===Physical Examination===
| | |
| | | 20–50 |
| ===Laboratory Findings===
| |
| | |
| ===Imaging Findings===
| |
| | |
| ===Other Diagnostic Studies===
| |
| | |
| ==Treatment==
| |
| ===Medical Therapy===
| |
| | |
| ===Surgery===
| |
| | |
| ===Prevention===
| |
| | |
| ==Reference==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Endocrinology]]
| |
| | |
| {{WS}}
| |
| {{WH}}
| |
Phenotype:
Classic salt wasting
Classic simple virilizing
Nonclassic
♂
♀
♂
♀
♂
♀
Age at diagnosis
Newborn-6m
Newborn-1m
2–4 y
Newborn-2 y
Child-adult
Child-adult
Genitalia
Normal
Ambiguous
Normal
Ambiguous
Normal
+/− ↑ clitoris
Aldosterone
↓
Normal
Normal
Renin
↑
May be ↑
Normal
Cortisol
↓
↓
Normal
17-OH-progesterone
>20,000 ng/dl
>10,000–20,000 ng/dl
1,500–10,000 ng/dl (ACTH-stimulated)
Testosterone
↑ In pre-puberty only
↑
↑ In pre-puberty only
↑
Variably ↑ in pre-puberty only
Variably ↑
Treatment
Glucocorticoid+ mineralocorticoid (+ sodium)
Glucocorticoid (+ mineralocorticoid)
Glucocorticoid, if symptomatic
Somatic growtha
-2-3 sd, husky-obese
-1-2 sd
?-1 sd
Incidenceb
1/20,000
1/60,000
1/1000
Typical mutationsc
Deletion
I172N
V281L
Large conversion
nt 656g
P30L
nt 656g (“intron 2 g”)
G110Δ8nt
I236N/V237E/M239K
Q318X
R356W
% Enzymatic activityd
0
1
20–50